157 related articles for article (PubMed ID: 17966792)
1. [What about the controversy regarding rosiglitazone].
Scheen AJ; De Flines J; Paquot N
Rev Med Liege; 2007 Sep; 62(9):560-5. PubMed ID: 17966792
[TBL] [Abstract][Full Text] [Related]
2. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
3. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
4. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
5. After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf KI; Taegtmeyer H
Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
[TBL] [Abstract][Full Text] [Related]
6. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
7. The long Avandia endgame.
Mullard A
Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
[No Abstract] [Full Text] [Related]
8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone and the FDA.
Krall RL
N Engl J Med; 2007 Oct; 357(17):1776-7; author reply 1777. PubMed ID: 17969232
[No Abstract] [Full Text] [Related]
10. FDA advisers favor easing rosiglitazone restrictions.
Traynor K
Am J Health Syst Pharm; 2013 Jul; 70(14):1184-5. PubMed ID: 23820451
[No Abstract] [Full Text] [Related]
11. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
12. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
14. The new rosiglitazone story: its place today in type 2 diabetes management.
Ambery P; Pandya B
Prim Care Diabetes; 2009 Feb; 3(1):57-9. PubMed ID: 19269912
[TBL] [Abstract][Full Text] [Related]
15. Actos and Avandia in type 2 diabetes. Where do they fit?
Clark W
Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078
[No Abstract] [Full Text] [Related]
16. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
17. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
18. Avandia outcome may signal change in epidemiologists' sway.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
[No Abstract] [Full Text] [Related]
19. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Krumholz HM
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986
[No Abstract] [Full Text] [Related]
20. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]